Alligator Energy to raise $1.1M

|

Published 29-MAY-2018 14:45 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Alligator Energy (ASX:AGE) is looking to raise up to $1.1 million via a rights issue.

The funds AGE is raising now will be used immediately on an initial cobalt nickel drilling program at its Piedmont Project in Northern Italy. The company is also looking to attract direct investment into its key drill-ready uranium exploration asset, the TCC4 prospect, with the aim to fund a future drilling program.

AGE is an ASX-listed explorer centred on uranium and energy-related minerals — primarily cobalt-nickel. The company is focused on the discovery of large economic high-grade energy-related metal deposits (uranium, nickel, cobalt) with clear pathways for approval and development.

In AGE’s energy portfolio are the Piedmont Cobalt-Nickel-Copper Project in Italy and the Alligator Rivers Uranium Projects in the Northern Territory.

AGE this morning announced a 1:3.5 non-renounceable rights issue at $0.007 per share, plus 1 attaching option for every 2 new shares. The funds raised will be used for the following purposes:

  • Attracting direct investment into AGE’s key drill-ready uranium exploration asset, the TCC4 prospect, with the aim to fund a future drilling program
  • Undertaking a focused initial drilling program at the Piedmont Cobalt–Nickel Project, based on a successful outcome from the Phase 1 geochemical and geophysics program and approval of drilling permits (application is currently underway)
  • Maintaining AGE’s uranium interests and assets in the ARUP
  • Working capital requirements

The offer has received support from a number of key shareholders, investors and brokers who have indicated their interest in taking up their shareholder entitlement and/or any potential shortfall shares.

It’s worth noting that this is an early stage play and investors should seek professional financial advice if considering this company for their portfolio.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X